US FDA puts Kezar Life Sciences’ lupus treatment trial on hold after patient deaths By Reuters Read more
“LEQEMBI” Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel By Investing.com Read more
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease Read more
Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal By Reuters Read more